Tessera Therapeutics

In case you missed it, our CSO, Mike Holmes, recently spoke to @DrugTargetRev about the RNA #GeneWriters data we presented at #ASGCT2024. Read the article to learn more about the progress of our #GeneWriting platform in alpha-1 antitrypsin deficiency (AATD): https://lnkd.in/exCSwezU

Last week, #TeamTessera gathered in our backyard at #TheBlockatBoyntonYards for Friends & Family Day!   At Tessera, we value our employees' hard work and tenacity. To help them recharge, we offer flexible work arrangements so they can spend quality time with loved ones. We understand the importance of connection, and opportunities like this allow us to bridge our professional and personal lives in meaningful ways.   #Community #SummerMemories #FriendsandFamily #Flexibility

Tune in to hear CGTLive's latest episode where our CEO, Mike Severino, discussed Tessera's Gene Writing and delivery platforms and our advancements towards in vivo gene editing at #ASGCT2024. Learn more about the progress we are making across multiple programs and how these cutting-edge technologies are paving the future of genetic medicine:  https://lnkd.in/eCFUdHsq

Our annual summer outing at Fenway Park was a hit! ⚾ Enjoying quality time with colleagues, along with their friends and families reinforces the positive and supportive environment we've cultivated here at Tessera. We believe these moments of team bonding contribute to enhanced trust, productivity, and a foundation for continued success. #TeamTessera #SummerOuting #Redsox #CompanyCulture #Community

Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all. Hear more from Flagship Founder and CEO Noubar Afeyan: https://lnkd.in/egcEgNrR

In case you missed it, we announced non-human primate data showing therapeutically relevant levels of in vivo rewriting of the gene responsible for alpha-1 antitrypsin deficiency at the Federation of American Societies for Experimental Biology (FASEB) 2024 Genome Engineering conference. Read more about the data here: https://lnkd.in/edAJUStY

This June, our #TesserOUT ERG championed inclusion with a month of action. From marching in the Boston Pride Parade to hosting vibrant company-wide celebrations and partnering with LGBTQIA+-owned businesses, they fostered a welcoming community for all. At Tessera, we understand the journey for equality continues, and remain committed to building a more inclusive future, year-round. Learn more about life at Tessera: https://bit.ly/4bbx3ZA #Pride2024 #TeamTessera #Inclusion #Diversity

This year at the 2024 #MontySummit, our CEO, Michael Severino, spoke about the potential impact of #GeneticMedicine on patients living with serious diseases. At Tessera, we're building the #FutureofGeneticMedicine, a field we believe will become a new pillar in medicine.

We’re attending Biotechnology Innovation Organization’s #BIO2024 conference! Anne-Virginie Eggimann, our Chief Regulatory Officer, will be speaking on a panel discussing the latest guidance in platform product innovation. Mark your calendars and register now: https://lnkd.in/eBVwb3gh

At #ASGCT2024, our CEO, Michael Severino, was featured on an episode of BiotechTV diving deeper into the remaining unmet need for patients with #SickleCellDisease and the rapid progress of our in vivo rewriting therapies toward the clinic. Watch the full episode for our latest advancements across our #GeneWriting and delivery platforms.